Background-In studies on the possible role of viruses in the aetiopathogenesis of Alzheimer's disease, herpes simplex virus type 1 (HSV1) DNA was detected by the polymerase chain reaction (PCR) in a high proportion of normal elderly people and of patients with Alzheimer's disease. The combination of HSV1 and a host factor, the type 4 allele of the gene for apolipoprotein E, is a strong risk factor for the disease. Methods-Brain specimens were examined for another herpes virus, varicella zoster (VZV), which, like HSV1, is neurotropic, has a predilection for residing latently in the peripheral nervous system, and can reactivate. Results-Using primers for sequences in the VZV origin of replication gene or thymidine kinase gene, VZV DNA was not found in any of 24 samples (18 HSV1 positive), from 17 patients with Alzheimer's disease, nor in 20 samples (12 HSV1 positive from 12 aged normal people. Hybridisation of the PCR products with a radiolabelled oligonucleotide probe capable of detecting less than 10 copies of the target sequence, confirmed the absence of VZV DNA. Conclusion-The presence of one neurotropic virus-HSV1-and the absence of another-VZV-in aged human brains is consistent with a role for HSV1 in the aetiology of Alzheimer's disease.
whether this results from exogenous or endogenous infection-that is, from new infection or from migration to the CNS of reactivated virus from the PNS.
Other common viruses-for example, measles virus-can, again in rare cases, cause serious neurological disease, even after persisting for many years in the host without any apparent ill effects. HSV1 has been proposed as a possible aetiological agent for Alzheimer's disease partly because of its propensity for residing latently in nervous tissue and partly because in acute herpes encephalitis (HSE), it affects the regions of the brain which are those most affected in Alzheimer's disease. However, until recently, it was uncertain whether or not HSV1 (or VZV) could reside latently in the CNS. Conflicting results (see review2)
were obtained from studies on HSV1 using dot or Southern blotting or in situ hybridisation: some authors claimed to detect the viral DNA in brains from normal subjects and from patients with Alzheimer's disease, whereas others failed to do so. The sensitivity of the methods used, though, was such that HSV1 DNA would have been detectable only if present at a level of at least one copy per cell genome.
With the advent of the polymerase chain reaction (PCR), detection of viruses in general in the CNS became a much more feasible proposition. We have used PCR to investigate brain specimens from normal people and from patients with Alzheimer's disease for the presence of HSV1 DNA. We have detected the viral DNA in a high proportion of elderly normal subjects and of patients with Alzheimer's disease; the infection seems to be latent and is present usually in the temporal and frontal cortex and hippocampus-the regions most affected in Alzheimer's disease.3 Viral DNA is absent in the occipital cortex-a region much less affected in the disease. We have not found the viral DNA in brain specimens from younger people. 720C (extension) step was continued for five minutes. We routinely checked for the absence of interference in our PCR assays by using primers for a human DNA sequence-within the HGPRT gene-in the same tube as primers for VZV DNA sequences; results were accepted only if the sample was positive for HGPRT. Possible cross contamination was routinely monitored using a buffer "blank" which had been subjected to the same procedures as the brain samples. Solution hybridisation of PCR products with an end labelled oligonucleotide probe internal to the OR amplified sequence, 13 followed by autoradiography, was used for determining the specificity of amplification; also, using amplified serial dilutions of purified VZV DNA, the sensitivity of detection of amplified VZV OR DNA was estimated.
Results Figure 1 shows the results for eight samplestwo normal aged subjects, six with Alzheimer's disease-of brain DNA using primers for the VZV OR gene sequence, and for the human HGPRT gene sequence. There was no evidence of VZV DNA in any of the samples and this was true of a further 18 normal and 18
Alzheimer's disease samples tested (table). 'RT sequence in all samples, showed that no interference was occurring in the PCR. As a further check, two brain DNA samples-one Alzheimer's disease, one normal which showed no amplified VZV product were each mixed with DNA from the VZV infected cells that is, with known positives, and the mixtures were tested by PCR. Figure 2 shows that amplification of the positives was obtained, indicating that the negative brain samples contained no interfering contaminant. Three Alzheimer's disease and three aged normal brain DNA samples were tested further using primers for the VZV TK sequence and showed similarly negative results. VZV immediate early and early genes seem to be expressed in latency and these are polyadenylated; it has therefore been suggested that cells latently infected with VZV might be "recognised" by the host immune system,'9 resulting presumably in a restricted extent of reactivation and hence reducing the likelihood of entry into the CNS.
Thus the presence of HSV1 and the absence of VZV, another neurotropic herpes virus with a similar propensity for latency, in the CNS of many aged subjects and patients with Alzheimer's disease-and the association of HSV1 in the patients with Alzheimer's disease with possession of an apoE4 allele-suggest that HSV1, but not VZV, plays a specific and major part in the aetiopathogenesis of Alzheimer's disease.
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